Comprehensive analysis of complement activation in a hydroxyurea-treated patient cohort with sickle cell disease.

ABSTRACT:

Abstract

Sickle cell disease (SCD) is an understudied, life-threatening genetic disorder affecting ∼300 000 infants yearly with limited treatment options. The complement system, a critical part of innate immunity, has emerged as a contributor to SCD pathophysiology, thus presenting a potential new treatment target. Our aim was to assess complement activity in children with SCD receiving hydroxyurea (HU) therapy during vaso-occlusive crisis (VOC) and steady state. Blood samples were collected from 46 pediatric patients with SCD during VOC (early and late) and steady state, with control samples from healthy volunteers. Clinical data were obtained from patient records, and patient heme levels were measured using colorimetric assay. Complement deposition on endothelial cells (ECs) was

SUBMITTER: Diatlov D 

PROVIDER: S-EPMC12917534 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature